Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
March 16, 2016Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration

A randomized, placebo-controlled, double-blind phase IIb trial evaluating the safety and efficacy of tirasemtiv in patients with amyotrophic lateral sclerosis

View Full Paper
Ask AI
Bookmark
Share

Authors

JSJeremy M. ShefnerBarrow Neurological InstituteAWAndrew A. WolffWashington School of PsychiatryLMLisa MengCytokinetics (United States)

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Shefner et al. (2016) studied this question.

synapsesocial.com/papers/6a973016ee2df1f3f68e3d24https://doi.org/10.3109/21678421.2016.1148169
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1El Escorial revisited: Revised criteria for the diagnosis of amyotrophic lateral sclerosis2000 · 5,498 citations
  2. 2A randomized, placebo-controlled trial of topiramate in amyotrophic lateral sclerosis2003 · 203 citations
  3. 3Phase II screening trial of lithium carbonate in amyotrophic lateral sclerosis2011 · 70 citations
  4. 4A phase II−III trial of olesoxime in subjects with amyotrophic lateral sclerosis2014 · 133 citations
  5. 5The relationship between tirasemtiv serum concentration and functional outcomes in patients with ALS2013 · 14 citations